Status:
COMPLETED
Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages
Lead Sponsor:
Rennes University Hospital
Conditions:
History of Exposure to Silica or Asbestosis
Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MD...
Detailed Description
Patients with a proven history or current exposure will have 4 EDTA tubes drawn, approximately 24mL of fresh whole blood for efferocytosis assessment and : * 2 x 6mL serum tubes for the assessment of...
Eligibility Criteria
Inclusion
- Patient older than 18 Yo
- Addressed to the department of occupational disease
- With a history of asbestosis or silica exposure evaluated by a dedicated questionnaire and a throughout examination of the history of occupations, according to standard procedures for the follow-up of at risk workers.
- Persons who received an oral and written information on the protocol and signed the informed consent form
Exclusion
- Pregnant or breastfeeding women
- Subject legally protected (under judicial protection, guardianship), persons deprived of liberty
Key Trial Info
Start Date :
March 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2021
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04473742
Start Date
March 31 2021
End Date
December 15 2021
Last Update
January 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Rennes
Rennes, France, 35033